7 Best Peptides for Diabetic Wounds

What to Know Before Choosing a Peptide for Diabetic Wounds

Diabetic wounds fail to heal for several reasons at once. The tissue is chronically inflamed, blood vessel formation is impaired, skin cells move more slowly toward the wound surface, and bacterial biofilms resist standard treatment. That layered biology is exactly why so many different peptides have been studied for this goal: each one enters the problem at a different point. Some promote new blood vessel growth. Some accelerate the migration of skin cells across the wound. Others target bacterial load or modulate the immune response that keeps the wound stuck in an inflammatory loop.

A peptide earns a place on this list because people use it, or are actively discussing using it, for diabetic wound healing. That standard includes FDA-approved therapies, compounds prescribed through telemedicine, and research-only peptides that circulate primarily in community protocols and preclinical literature. Evidence strength is stated honestly for each compound rather than used as a filter. A peptide with only animal-model data belongs here with that limitation stated plainly, just as much as one with completed human trials.

The numbers in front of each entry give the list a shape. They are not a ranking of which peptide is best. The order reflects how prominently each compound appears in research and in real-world use for this goal. The right compound for any individual depends on their situation, their wound type, and a conversation with whoever is managing their care.

One field-wide note before the entries: the International Working Group on the Diabetic Foot issued 2023 guidelines advising against using topical bioactive peptide products solely for wound healing in the absence of a confirmed infection. Their position is that standard care, meaning proper debridement, pressure offloading, and vascular optimization, should not be displaced by bioactive agents that lack an equivalent evidence base. That context applies to most of what follows.

1. Becaplermin: The Only FDA-Approved Peptide Therapy for Diabetic Wounds

Becaplermin is a recombinant human platelet-derived growth factor. It holds the distinction of being the only peptide-based therapy that has received FDA approval specifically for diabetic wounds, an approval it received in 1997. That approval covers lower-extremity diabetic neuropathic ulcers, the type that arise from nerve damage rather than vascular disease alone. It is applied topically as a gel, once daily, to clean and debrided wounds.

The clinical evidence behind becaplermin is the strongest of any peptide in this space. In controlled trials, it achieved complete wound closure in roughly 50 percent of patients over a 20-week period, compared to around 35 percent for patients using the vehicle gel without the active compound. That is a real and meaningful difference, which is why it has remained the reference point for comparison in diabetic wound peptide research for nearly three decades.

Becaplermin works by binding to platelet-derived growth factor receptors on cells in and around the wound. Activating those receptors signals fibroblasts and other repair cells to move toward the wound and begin building new tissue. Think of it as delivering the "repair crew needed here" signal that the diabetic wound environment fails to generate on its own. The approval carries important restrictions: it is not intended for wounds that are infected, contain dead tissue, or involve cancer, which limits its use in more complex diabetic foot cases.

For the reader, becaplermin is the one compound on this list that a physician can prescribe through standard channels in the United States for an on-label indication. That is a significant practical distinction from every other entry here.

2. BPC-157: The Community Favorite for Angiogenesis and Tissue Repair

BPC-157, which stands for Body Protection Compound-157, is a synthetic peptide derived from a protein found in the stomach lining. It has become one of the most widely discussed peptides in biohacking and research communities for wound healing and tissue repair, and the diabetic wound context is a specific area where it comes up consistently.

The mechanistic story for BPC-157 in diabetic wounds centers on angiogenesis, the process of forming new blood vessels. Diabetic tissue is chronically underperfused: the small vessels that should be delivering oxygen and nutrients to the wound are damaged or dysfunctional. BPC-157 has been shown in animal studies to establish a granulation tissue vascular bed, specifically by promoting the formation of CD31-positive microvessels. CD31 is a protein that marks the inner lining of blood vessels and serves as a reliable marker for new vessel development. Driving that process in poorly perfused tissue is directly relevant to what makes diabetic wounds so hard to close.

In diabetic mouse studies using the db/db model, a well-established animal model for type 2 diabetes, BPC-157 achieved approximately 96 percent wound closure by day 14, compared to around 74 percent in vehicle-treated controls. Those are animal numbers, and the caution that comes with them is real: no specific human clinical trial has been published for BPC-157 in diabetic wounds as of 2026. What exists is a strong preclinical picture, genuine mechanistic rationale, and widespread community-reported use among people pursuing wound healing and tissue repair protocols.

BPC-157 also appears to work additively with GHK-Cu when the two are combined in animal models, which is part of why the two show up together in community wound healing protocols.

3. GHK-Cu: The Collagen Synthesis and Antioxidant Compound

GHK-Cu is a copper-binding tripeptide found naturally in human plasma. Copper is essential to collagen cross-linking and several antioxidant enzymes, and GHK-Cu acts as a carrier that delivers copper to cells that need it while also producing its own signaling effects. It has been studied for skin biology and wound healing for decades, and in a diabetic wound context it addresses several of the specific biological failures that keep those wounds from closing.

Diabetic wounds accumulate oxidative stress, an imbalance between damaging reactive oxygen species and the cell's ability to neutralize them. GHK-Cu provides antioxidant protection by binding toxic lipid peroxidation products, which are byproducts of oxidative damage to cell membranes. It also accelerates collagen synthesis, promotes fibroblast proliferation and migration, and supports remodeling of the extracellular matrix, the scaffolding that gives healed tissue its structure. In animal models for diabetic wounds, studies have shown approximately 92 percent wound closure by day 14, along with increased fibroblast density when GHK-Cu is combined with IGF-1.

There is an important safety note specific to diabetic wounds. The International Working Group on the Diabetic Foot lists topical GHK-Cu among compounds that carry a strong caution when used as a standalone therapy for wound healing in the absence of confirmed infection. The concern is that topical bioactive agents can increase moisture at the wound site, leading to periwound maceration, which is the breakdown of healthy skin surrounding the wound. That complication can slow healing rather than accelerate it and can also displace the standard-of-care steps that carry the strongest evidence.

GHK-Cu has an FDA submission pending for expanded clinical applications. It is currently available in cosmetic topical formulations and as a research-grade compound. Using it for diabetic wounds falls outside its current approved scope, and the IWGDF caution above is a real clinical consideration.

4. TB-500: For Cellular Migration and Chronic Wound Environments

TB-500 is a synthetic version of Thymosin Beta-4, a peptide the body produces naturally that plays a role in how cells move, differentiate, and respond to injury. It has been studied for wound healing and angiogenesis, and it shows up regularly in research discussions about chronic wounds, including the diabetic wound context.

Rather than stimulating one specific repair pathway, TB-500 broadly promotes cellular migration and differentiation. In a diabetic wound, where one central failure is that keratinocytes and fibroblasts, the cells responsible for re-covering the wound surface and rebuilding underlying tissue, move more slowly than they should, a compound that specifically drives cellular migration is addressing a real bottleneck. TB-500 also reduces inflammation and stimulates the formation of new blood vessels, both of which are relevant in the chronic, oxygen-depleted environment of a diabetic wound.

Laboratory studies confirm wound healing acceleration and angiogenesis in chronic wound models, and TB-500 is used in veterinary contexts for diabetic animals. It also has a following in biohacking communities for tissue repair and recovery protocols more broadly.

The clinical picture in humans for diabetic wound healing specifically has not been established. No published human clinical trial data exists for this use as of 2026. Community-reported use is real and widespread, particularly in the context of slow-healing wounds and injury recovery, but the evidence is experiential rather than clinical when it comes to diabetic wounds specifically. TB-500 is a research-grade compound and is not approved for this application.

5. LL-37: The Endogenous Antimicrobial Peptide

LL-37 occupies a distinct position on this list because it is not an external compound addressing a deficiency in a general healing pathway. It is a human antimicrobial peptide the body produces naturally, and in diabetic skin its levels are measurably reduced. That reduction is part of why diabetic wounds are so susceptible to infection and so slow to clear bacterial colonization, which in turn is part of why those wounds remain chronic.

LL-37 kills bacteria by disrupting bacterial cell membranes, a mechanism that is difficult for bacteria to develop resistance against in the way they develop resistance to antibiotics that target specific cellular machinery. Beyond its antimicrobial activity, LL-37 promotes keratinocyte migration, enhances angiogenesis, and has immunomodulatory effects, meaning it helps regulate the immune response at the wound site rather than simply suppressing or amplifying it.

LL-37 has more human clinical data than most compounds on this list outside of becaplermin. A 2014 Phase I and II trial tested it in venous leg ulcers, not diabetic foot ulcers, and found it to be safe with dose-response activity, though complete wound closure was not achieved within the trial period, a limitation the researchers attributed to trial duration. More recently, a clinical trial specifically in diabetic foot ulcers with mild infections showed enhanced healing rates with topical LL-37 cream, which is a more directly relevant data point.

The concern the IWGDF raises about topical antimicrobial peptides is the potential for antimicrobial resistance with prolonged use. That said, LL-37 is most specifically relevant when wound infection is present, which is the context in which the IWGDF does not discourage bioactive agents. LL-37 is a research-stage compound and is not FDA-approved for diabetic wound healing.

6. QHREDGS: The Preclinical Standout for Re-Epithelialization

QHREDGS is a peptide derived from angiopoietin-1, a protein involved in blood vessel stabilization. It is largely unfamiliar outside academic wound healing research, but it has produced some of the most striking preclinical results specifically in diabetic wound models and deserves a place on any honest survey of this field.

The mechanism centers on integrin signaling. Integrins are proteins on the cell surface that act as attachment points, allowing cells to grip the extracellular matrix and pull themselves forward. QHREDGS binds beta-1-containing integrins and activates Akt and MAPK signaling pathways inside the cell. The practical result is that keratinocytes, the skin cells that must crawl across the wound surface to close it, attach more effectively, survive longer, and move in coordinated groups rather than as isolated cells. That coordinated movement, called collective migration, is how wounds close efficiently, and it is significantly impaired in diabetic tissue.

The preclinical numbers are notable. In db/db diabetic mice, QHREDGS accelerated wound closure by approximately 167 percent compared to untreated wounds. In a head-to-head comparison with a clinically approved collagen dressing, it achieved roughly 60 percent faster closure. In one study, a single application produced complete wound closure in three weeks.

QHREDGS is at an early stage: its data comes from mouse models, it is not commercially available as a consumer product, and human trials have not been reported. The gap between those preclinical results and tested human outcomes is wide. But the specificity of those results for diabetic wound biology, not just general wound healing, and the fact that it is an active area of published research, makes it a compound worth understanding for anyone following this field closely.

7. MOTS-c: For the Metabolic and Inflammatory Roots of Diabetic Wounds

MOTS-c is a mitochondria-derived peptide, encoded in the mitochondrial genome rather than the nuclear genome. It was identified relatively recently and has been studied primarily in metabolic regulation and insulin sensitivity. Its relevance to diabetic wounds comes from a different angle than most entries here: it targets two of the upstream biological failures that make diabetic tissue a poor healing environment.

The first is macrophage polarization. Macrophages are immune cells central to wound healing. In a healthy wound they transition from a pro-inflammatory state, called M1, to a pro-reparative state, called M2, as healing progresses. In diabetic wounds, macrophages tend to remain stuck in the M1 state, which sustains chronic inflammation and prevents the tissue from progressing to repair. MOTS-c promotes the transition from M1 to M2 polarization, directly addressing that stuck-inflammatory-phase problem.

The second is AGE-RAGE signaling. Advanced glycation end products are compounds that accumulate in diabetic tissue as a result of prolonged high blood sugar, and they bind to RAGE receptors on cells throughout the body. That binding drives oxidative stress, inflammation, and cellular dysfunction, and it is one of the core mechanisms by which chronic hyperglycemia damages tissue. MOTS-c reduces RAGE protein expression, working upstream of the wound-level problem rather than only at the wound surface.

In animal studies using a streptozotocin high-fat diet diabetic model, MOTS-c achieved 78 to 84 percent wound closure at day 14, alongside increases in VEGF-A expression, which is the primary signaling molecule for new blood vessel growth, and reductions in RAGE protein. All of this is preclinical data from animal models. No human clinical trial data has been published for MOTS-c in diabetic wound healing as of 2026. It is a research-grade compound. But its targeting of metabolic mechanisms specific to diabetic tissue, rather than generic wound biology, gives it a distinct place in this field.

How These Peptides Compare

Frequently Asked Questions

Is there a peptide that is FDA-approved for diabetic wounds?

Yes, one: becaplermin. It is a recombinant human platelet-derived growth factor approved in 1997 for lower-extremity diabetic neuropathic ulcers. No other peptide has received FDA approval specifically for diabetic wound healing as of 2026. All other compounds on this list are either research-grade, currently in clinical trials, or approved for different indications.

Why do most peptides for diabetic wounds have only animal data?

Diabetic wound healing involves several overlapping biological failures simultaneously, and designing human trials that isolate one peptide's contribution is methodologically complex and expensive. Most peptides in this space remain in the preclinical phase because the path from a promising animal result to a completed human trial is long, not because research interest is lacking. A handful, including becaplermin, Granexin, and PL-5, have advanced to human trials, but they are still the exception rather than the rule.

Can peptides replace standard diabetic wound care?

No, and clinical guidelines are clear on this point. The International Working Group on the Diabetic Foot advises that topical bioactive agents, including peptide-based products, should not displace the standard-of-care steps with the strongest evidence: proper debridement of dead tissue, pressure offloading to reduce mechanical stress on the wound, and vascular assessment and optimization. Peptides may eventually complement that standard of care as evidence matures, but they are not a substitute for it.

What is the difference between antimicrobial peptides and tissue-repair peptides for diabetic wounds?

Antimicrobial peptides like LL-37 primarily address the bacterial load that keeps diabetic wounds chronically infected and inflamed, often by disrupting bacterial membranes directly. Tissue-repair peptides like BPC-157, GHK-Cu, and QHREDGS work on the healing side: promoting new blood vessel growth, accelerating cell migration, rebuilding collagen, and reducing oxidative damage. Many diabetic wounds have both problems simultaneously, which is why combination approaches and multi-mechanism compounds attract substantial research attention.

Are any of these peptides available through a doctor?

Becaplermin is available by prescription through standard medical channels. LL-37 has been tested in clinical trials and may be accessible through specific clinical research programs. The remaining compounds on this list are research-grade and fall outside standard medical prescribing in the United States. Some may be accessible through functional medicine practitioners or research settings, but they lack FDA approval for this use and are not part of routine wound care practice.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for diabetic wounds in one place.